Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (March 2020)
22 slides from Somnomed's investor presentation, Mar 25, 2020
Slide 1: Investor Presentation: Trading update and capital raising
For personal use only Investor Presentation Trading update and capital raising March 2020
Slide 2: Disclaimer & Regulatory Disclosure
DISCLAIMER & REGULATORY DISCLOSURE For personal use only The following notice and disclaimer applies to this investor presentation (Presentation) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Pres
Slide 3: Disclaimer & Regulatory Disclosure
DISCLAIMER & REGULATORY DISCLOSURE For personal use only Investment risk An investment in New Shares is subject to known and unknown risks, some of which are beyond the control of the Group, including possible delays in repayment and loss of principal and income invested. The Company does not guaran
Slide 4: Contents
Contents For personal use only 1.Trading conditions update 2.Outlook 3.Capital raising 4.Key risks 5.Foreign selling jurisdictions
Slide 5: 1. Trading conditions update
For personal use only 1. Trading conditions update
Slide 6: Trading conditions update
Trading conditions update For personal use only SomnoMed’s trading performance in January and February SomnoMed has the following implemented significant cost saving measures to date: 2020 was on target and in accordance with guidance. Revenues were growing > CEO salary reduced by 50% until further
Slide 7: First-half ending December 2019 summary
First-half ending 31 December 2019 summary For personal use only SomnoMed’s core revenue growth +15% over prior year Successful launch of the digital SomnoDent® Avant EBITDA* $3m and +130% over prior year Key strategic contract signed with App-Nea LLC North America first-half revenue growth +26% and
Slide 8: Prior to COVID-19, SomnoMed was performing to expectations
Prior to the impact of COVID-19, SomnoMed was performing to expectations For personal use only (Financials – January and February 2020*) Total SomnoMed core revenue growth Revenue growth (%) Jan-20 Feb-20 Jan + Feb FY20 North America 33% 32% 32% Europe 12% 12% 12% APAC (14%) 3% (6%) SomnoMed Core 17
Slide 9: 2. Outlook
For personal use only 2. Outlook
Slide 10: Outlook for the rest of FY20
Outlook for the rest of FY20 For personal use only Given the uncertain extent and duration of the impact of COVID-19 on the Company, current outlook is largely unknown Actions are in place to preserve cash and protect the business Further actions will be taken should necessity dictate The focus of t
Slide 11: 3. Capital Raising
For personal use only 3. Capital Raising
Slide 12: Capital raising details
Capital raising details For personal use only • A$15.5m offer comprising a 1 for 3.24 pro-rata accelerated non-renounceable entitlement offer (“Entitlement Offer”) Offer Size and • Approximately 19.4 million new SomnoMed shares to be issued (“New Shares”), representing 30.9% of current SomnoMed shar
Slide 13: Capital raising details
Capital raising details For personal use only Use of proceeds • The Entitlement Offer proceeds will be used for working capital purposes • A nominee has been appointed, and approved by ASIC, for the purposed of section 615 of the Corporations Act, so as to deal with new Shares that would have otherw
Slide 14: Timetable
Timetable For personal use only Procedure Step Date Procedure Step Date Announcement of Entitlement Offer Wednesday, 25 March Information Booklet and Entitlement and Acceptance Form sent Wednesday, 01 April to Retail Investors Institutional Offer opens Wednesday, 25 March Retail Entitlement Offer op
Slide 15: 4. Key risks
For personal use only 4. Key risks
Slide 16: Risks
Risks For personal use only SomnoMed is subject to a number of risks and other factors that may impact both on its Coronavirus (COVID 19) event Changes potentially affecting prices charged future performance and the market price at which its Shares trade. Broadly, these risks The specific risks asso
Slide 17: 5. Foreign selling jurisdictions
For personal use only 5. Foreign selling jurisdictions
Slide 18: Offer restrictions
Offer restrictions For personal use only This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in Other than in the entitlement offer, the New Shares may only be offered or sold in New Zealand (or allotted with a view to being which it wo
Slide 19: Contact
Contact For personal use only Chief Executive Officer: Mr Neil Verdal-Austin Chief Financial Officer: Mr Hervé Fiévet Address: 20 Clarke Street, Crows Nest, Sydney 2065 Telephone: 02 9467 0400 Website: www.somnomed.com
Slide 20: Appendix A: Underwriting Agreement Summary
For personal use only Appendix A: Underwriting Agreement Summary
Slide 21: Summary of Underwriting Arrangements
SUMMARY OF UNDERWRITING ARRANGEMENTS For personal use only Wilsons Corporation Finance Limited (Wilsons) is acting as sole lead manager and underwriter of the Entitlement Offer. SomnoMed has entered into an underwriting agreement with Wilsons in respect of the Entitlement Offer (Agreement). The Agre
Slide 22: Summary of Underwriting Arrangements (cont'd)
SUMMARY OF UNDERWRITING ARRANGEMENTS (CONT’D) For personal use only r) (corrective statement) in the opinion of Wilsons (acting reasonably) SomnoMed becomes required to give, or gives, in respect of a cleansing notice issued in connection with the Entitlement Offer which is defective, a notice given